Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 7/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16159744 | 0.89 | PDPK1 (0.44) | CYP2A6PDPK1PDK2KDRCHEK2 | |
| SCHEMBL16159492 | 0.88 | PDPK1 (0.49) | CYP2A6PDPK1PDK2KDRPTGDR2 | |
| SCHEMBL16159313 | 0.88 | PDPK1 (0.51) | CYP2A6PDPK1PDK2KDRPTGDR2 | |
| SCHEMBL16159143 | 0.84 | RAB9A (0.40) | CYP2A6PDPK1PDK2KDRCHEK2 | |
| SCHEMBL16159751 | 0.83 | CYP2A6 (0.44) | CYP2A6PDPK1PDK2KDRCHEK2 | |
| SCHEMBL16159447 | 0.79 | RAB9A (0.43) | PDPK1PDK2LOXL2RAB9ASYK | |
| SCHEMBL16159541 | 0.78 | PDPK1 (0.39) | CYP2A6PDPK1PDK2KDRPTGDR2 | |
| SCHEMBL16159750 | 0.78 | PDPK1 (0.36) | CYP2A6PDPK1KDRCHEK2PTGDR2 | |
| SCHEMBL16159779 | 0.78 | PDK2 (0.40) | PDK2KDRCHEK2 | |
| SCHEMBL16159288 | 0.78 | PDPK1 (0.40) | CYP2A6PDPK1PDK2KDRCHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160118598-A1 | ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | JNC CORPORATION (JP) | 2016-04-28 | — | — | US | disclosed |
| US-20160118598-A1 | ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | JNC CORPORATION (JP) | 2016-04-28 | — | — | US | disclosed |
| WO-2014163173-A1 | ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | JNC株式会社 (JP) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160118598-A1 | ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | HVCN1, VDAC1, SLC26A3 | CYP2A6 1206/4885PDPK1 4680/4885PDK2 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.